

# Ryan T Borne

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4673082/publications.pdf>

Version: 2024-02-01

25  
papers

531  
citations

759233

12  
h-index

752698

20  
g-index

26  
all docs

26  
docs citations

26  
times ranked

1186  
citing authors

#	ARTICLE	IF	CITATIONS
1	Use and Outcomes of Dual Chamber or Cardiac Resynchronization Therapy Defibrillators Among Older Patients Requiring Ventricular Pacing in the National Cardiovascular Data Registry Implantable Cardioverter Defibrillator Registry. JAMA Network Open, 2021, 4, e2035470.	5.9	0
2	Taking Time With the RP Interval in Narrow Complex Tachycardia. JAMA Internal Medicine, 2021, 181, 988-989.	5.1	0
3	Increased incidence of cavotricuspid isthmus atrial flutter following slow pathway ablation. Journal of Interventional Cardiac Electrophysiology, 2021, , 1.	1.3	0
4	Looking Back to Find the Missing P Wave and Diagnose a Narrow Complex Tachycardia. JAMA Internal Medicine, 2020, 180, 1526.	5.1	8
5	Impact of epicardial adipose tissue and catheter ablation strategy on biophysical parameters and ablation lesion characteristics. Journal of Cardiovascular Electrophysiology, 2020, 31, 1114-1124.	1.7	20
6	Continuous ablation improves lesion maturation compared with intermittent ablation strategies. Journal of Cardiovascular Electrophysiology, 2020, 31, 1687-1693.	1.7	4
7	Electrophysiologic testing for diagnostic evaluation and risk stratification in patients with suspected cardiac sarcoidosis with preserved left and right ventricular systolic function. Journal of Cardiovascular Electrophysiology, 2019, 30, 1939-1948.	1.7	26
8	Analysis of Temporal Trends and Variation in the Use of Defibrillation Testing in Contemporary Practice. JAMA Network Open, 2019, 2, e1913553.	5.9	7
9	Follow-Up After Catheter Ablation of Papillary Muscles and Valve Cusps. JACC: Clinical Electrophysiology, 2019, 5, 1185-1196.	3.2	8
10	Bipolar radiofrequency ablation creates different lesion characteristics compared to simultaneous unipolar ablation. Journal of Cardiovascular Electrophysiology, 2019, 30, 2960-2967.	1.7	22
11	Red Alert. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e006113.	4.8	1
12	Identification and Characterization of Sites Where Persistent Atrial Fibrillation Is Terminated by Localized Ablation. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e005258.	4.8	43
13	Use of Tissue Electric and Ultrasound Characteristics to Predict and Prevent Steam-Generated Cavitation During High-Power Radiofrequency Ablation. JACC: Clinical Electrophysiology, 2018, 4, 491-500.	3.2	26
14	Longer Duration Versus Increasing Power During Radiofrequency Ablation Yields Different Ablation Lesion Characteristics. JACC: Clinical Electrophysiology, 2018, 4, 902-908.	3.2	53
15	Outcomes Among Older Patients Receiving Implantable Cardioverter-Defibrillators for Secondary Prevention. Journal of the American College of Cardiology, 2017, 69, 265-274.	2.8	20
16	Healthcare After Implantable Cardioverter-Defibrillator Shocks. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	0
17	Implantable Cardioverter-Defibrillators for Secondary Prevention of Sudden Cardiac Death: A Review. Journal of the American Heart Association, 2017, 6, .	3.7	21
18	Survival After Secondary Prevention Implantable Cardioverter-Defibrillator Placement. JACC: Clinical Electrophysiology, 2017, 3, 20-28.	3.2	14

#	ARTICLE	IF	CITATIONS
19	Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration. BMC Cardiovascular Disorders, 2017, 17, 236.	1.7	125
20	Optimal utilization of implantable cardioverter-defibrillators: Are we there yet?. Heart Rhythm, 2015, 12, 2028-2029.	0.7	1
21	Tropheryma whipplei Endocarditis: A Two-patient Case Series. American Journal of Medicine, 2015, 128, 1364-1366.	1.5	5
22	Temporal Trends in Patient Characteristics and Outcomes Among Medicare Beneficiaries Undergoing Primary Prevention Implantable Cardioverter-Defibrillator Placement in the United States, 2006â€“2010. Circulation, 2014, 130, 845-853.	1.6	32
23	Implantable Cardioverter-Defibrillator Shocks. JAMA Internal Medicine, 2013, 173, 859.	5.1	92
24	Impact of Implantable Cardioverter-Defibrillator Therapy on a Secondary Prevention Populationâ€”Reply. JAMA Internal Medicine, 2013, 173, 2094.	5.1	0
25	Lixivaptan for Hyponatremiaâ€”The Numbers Game. JAMA - Journal of the American Medical Association, 2012, 308, 2345.	7.4	3